H1N1 influenza:
Responding to a pandemic
As H1N1 flu continues to make headlines across the world, GlaxoSmithKline is responding to the flu pandemic.
GSK is investing in the development of vaccines for the influenza A (H1N1) strain of flu and the increased production of the anti-viral Relenza through its own manufacturing facilities and through partnerships with other companies.
Announcements
Recent headlines
[an error occurred while processing this directive]
[an error occurred while processing this directive]
November 16, 2009
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
November 10, 2009
Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine
November 10, 2009
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
GSK News Services
Leading the way to make clinical trial data more transparent
Learn about flu treatment
Find health information
Save money on your prescriptions
Join GSK
Updated November 17, 2009
© 2001 - 2009 GlaxoSmithKline - All rights reserved